Procter & Gamble Health Ltd

Procter & Gamble Health Ltd

₹ 5,066 1.53%
14 Jun 4:01 p.m.
About

P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]

Key Points

Strong Brand Portfolio
Company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals and supplements. It has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion, Cosome and Livogen. [1]

  • Market Cap 8,412 Cr.
  • Current Price 5,066
  • High / Low 5,643 / 4,637
  • Stock P/E 39.3
  • Book Value 485
  • Dividend Yield 1.88 %
  • ROCE 45.5 %
  • ROE 33.5 %
  • Face Value 10.0

Pros

  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 27.9%
  • Company has been maintaining a healthy dividend payout of 70.6%

Cons

  • Stock is trading at 10.4 times its book value
  • The company has delivered a poor sales growth of 12.0% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
219 285 273 278 268 296 298 310 321 301 305 310 252
188 237 195 216 199 237 207 201 241 256 216 208 185
Operating Profit 31 48 78 62 69 59 91 109 80 45 89 102 67
OPM % 14% 17% 29% 22% 26% 20% 31% 35% 25% 15% 29% 33% 27%
3 2 3 5 2 3 3 5 5 5 6 5 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 8 7 7 7 6 7 7 8 6 6 6 7 7
Profit before tax 26 44 74 60 65 55 87 105 79 44 88 100 63
Tax % 40% 22% 25% 25% 21% 25% 26% 27% 25% 32% 26% 28% 26%
16 34 55 45 51 41 64 77 59 30 66 72 47
EPS in Rs 9.50 20.42 33.36 27.01 30.82 24.81 38.35 46.27 35.66 17.96 39.50 43.42 28.05
Raw PDF

Profit & Loss

Figures in Rs. Crores

Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 TTM
687 798 867 940 993 698 849 927 1,356 1,009 1,114 1,230 1,169
582 721 809 855 877 621 701 723 1,037 762 846 905 865
Operating Profit 106 77 59 85 116 77 148 204 319 246 268 325 303
OPM % 15% 10% 7% 9% 12% 11% 17% 22% 24% 24% 24% 26% 26%
20 21 20 22 24 74 768 48 66 18 13 18 19
Interest -0 -0 -0 -0 -0 -0 -0 -0 -0 1 0 1 1
Depreciation 9 10 13 23 25 19 21 17 29 30 27 28 27
Profit before tax 117 88 67 83 115 132 895 234 355 233 253 314 295
Tax % 33% 37% 35% 36% 31% 29% 6% 32% 28% 24% 24% 27%
78 56 43 54 79 94 839 159 254 177 193 229 214
EPS in Rs 47.23 33.66 26.04 32.27 47.67 56.57 505.27 95.64 153.07 106.51 115.98 138.24 128.93
Dividend Payout % 5% 25% 23% 23% 23% 27% 87% -0% 150% 122% 45% 44%
Compounded Sales Growth
10 Years: 6%
5 Years: 12%
3 Years: -3%
TTM: -5%
Compounded Profit Growth
10 Years: 11%
5 Years: 23%
3 Years: -4%
TTM: -11%
Stock Price CAGR
10 Years: 22%
5 Years: 5%
3 Years: -5%
1 Year: -1%
Return on Equity
10 Years: 27%
5 Years: 37%
3 Years: 28%
Last Year: 33%

Balance Sheet

Figures in Rs. Crores

Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023 Dec 2023
Equity Capital 17 17 17 17 17 17 17 17 17 17 17 17 17
Reserves 467 506 538 575 647 717 1,524 800 890 687 600 734 789
-0 -0 -0 -0 -0 -0 -0 -0 -0 8 3 12 11
111 125 154 192 215 258 219 250 269 275 269 338 260
Total Liabilities 594 648 708 784 879 991 1,759 1,067 1,176 986 888 1,101 1,077
75 85 110 132 111 115 104 101 101 104 112 144 143
CWIP 2 9 28 7 30 9 17 11 21 39 41 32 28
Investments 24 24 24 42 28 70 -0 -0 -0 -0 -0 -0 -0
494 530 547 603 711 797 1,639 954 1,053 843 736 925 906
Total Assets 594 648 708 784 879 991 1,759 1,067 1,176 986 888 1,101 1,077

Cash Flows

Figures in Rs. Crores

Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023
54 0 5 83 107 54 -130 235 247 170 236
-82 7 11 -68 -75 -48 1,270 165 -32 -26 -22
-0 -5 -17 -12 -15 -22 -30 -883 -387 -289 -98
Net Cash Flow -28 3 -1 4 17 -16 1,109 -483 -172 -145 116

Ratios

Figures in Rs. Crores

Dec 2012 Dec 2013 Dec 2014 Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Jun 2020 Jun 2021 Jun 2022 Jun 2023
Debtor Days 34 38 44 49 39 64 28 30 26 22 27 34
Inventory Days 160 153 162 140 145 243 154 139 113 138 124 136
Days Payable 48 37 40 55 67 128 124 106 105 209 185 239
Cash Conversion Cycle 146 154 166 134 118 179 58 63 34 -49 -34 -69
Working Capital Days 77 70 74 69 52 94 42 22 23 9 18 16
ROCE % 26% 18% 12% 15% 18% 16% 78% 29% 29% 38% 45%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82%
6.45% 5.88% 5.97% 6.57% 6.47% 6.05% 6.33% 6.72% 7.15% 7.38% 7.60% 6.24%
11.81% 8.36% 8.53% 7.91% 8.07% 12.62% 12.44% 12.31% 12.29% 12.30% 12.66% 13.72%
29.93% 33.94% 33.69% 33.71% 33.64% 29.51% 29.41% 29.14% 28.74% 28.50% 27.92% 28.22%
No. of Shareholders 58,81863,52565,53766,28965,72965,14863,83161,03058,85657,91956,73056,778

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents